Federated Hermes Inc. Increases Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Federated Hermes Inc. boosted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 13.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 137,561 shares of the medical research company's stock after purchasing an additional 16,338 shares during the period. Federated Hermes Inc. owned about 0.49% of Bio-Rad Laboratories worth $45,190,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Venturi Wealth Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after buying an additional 87 shares during the last quarter. Picton Mahoney Asset Management increased its stake in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the 4th quarter worth $33,000. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at about $38,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Up 5.7 %

BIO stock traded up $13.14 during midday trading on Friday, reaching $245.43. The company's stock had a trading volume of 362,886 shares, compared to its average volume of 319,448. The firm has a market capitalization of $6.87 billion, a price-to-earnings ratio of -3.77 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a fifty day simple moving average of $264.86 and a two-hundred day simple moving average of $314.68.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on BIO. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.